Advertisement
Screener

Scilex Holding Company (SCLX) Increase (Decrease) in Other Current Liabilities

2.8 / 5 stars · 68/120 Roast Me

Scilex Holding Company Increase (Decrease) in Other Current Liabilities

Scilex Holding Company (SCLX) reported Increase (Decrease) in Other Current Liabilities of -$3.66 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInOtherCurrentLiabilities · last filed 2026-08-14

  • Scilex Holding Company increase (decrease) in other current liabilities for the quarter ending 2024-09-30 was -$191.00K.
  • Scilex Holding Company increase (decrease) in other current liabilities for the quarter ending 2024-06-30 was -$205.00K, a 123.30% decline year-over-year.
  • Scilex Holding Company increase (decrease) in other current liabilities for the quarter ending 2024-03-31 was -$197.00K.
  • Scilex Holding Company increase (decrease) in other current liabilities for the quarter ending 2023-12-31 was -$192.00K.
  • Scilex Holding Company increase (decrease) in other current liabilities for fiscal 2023 was -$711.00K.
  • Scilex Holding Company increase (decrease) in other current liabilities for fiscal 2022 was -$392.00K.
  • Scilex Holding Company increase (decrease) in other current liabilities for fiscal 2021 was -$80.00K.
  • Scilex Holding Company increase (decrease) in other current liabilities for fiscal 2020 was -$604.00K.
Period endIncrease (Decrease) in Other Current Liabilities 3 monthIncrease (Decrease) in Other Current Liabilities 6 monthIncrease (Decrease) in Other Current Liabilities 6 month as first filedIncrease (Decrease) in Other Current Liabilities 9 monthIncrease (Decrease) in Other Current Liabilities 12 month
2026-06-30-$3.66M
10-Q · filed 2026-08-14
2024-09-30-$191.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-01-17
-$396.00K
derived: sum of 2 quarters · filed 2025-01-17
-$593.00K
10-Q · filed 2025-01-17
-$785.00K
derived: sum of 4 quarters · filed 2025-01-17
2024-06-30-$205.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13
-$402.00K
10-Q · filed 2024-08-13
-$594.00K
derived: sum of 3 quarters · filed 2024-08-13
-$1.82M
derived: sum of 4 quarters · filed 2025-01-17
2024-03-31-$197.00K
10-Q · filed 2024-05-13
-$389.00K
derived: sum of 2 quarters · filed 2024-05-13
-$1.61M
derived: sum of 3 quarters · filed 2025-01-17
-$733.00K
derived: sum of 4 quarters · filed 2025-01-17
2023-12-31-$192.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12
-$1.42M
derived: sum of 2 quarters · filed 2025-01-17
-$536.00K
derived: sum of 3 quarters · filed 2025-01-17
-$711.00K
10-K · filed 2024-03-12
2023-09-30-$1.22M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-01-17
-$344.00K
derived: sum of 2 quarters · filed 2025-01-17
-$519.00K
10-Q · filed 2025-01-17
-$656.00K
derived: sum of 4 quarters · filed 2025-01-17
2023-06-30$880.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13
$705.00K
10-Q · filed 2024-08-13
-$338.00K
10-Q · filed 2023-08-11
$568.00K
derived: sum of 3 quarters · filed 2024-08-13
$451.00K
derived: sum of 4 quarters · filed 2024-08-13
2023-03-31-$175.00K
10-Q · filed 2024-05-13
-$312.00K
derived: sum of 2 quarters · filed 2024-05-13
-$429.00K
derived: sum of 3 quarters · filed 2024-05-13
-$555.00K
derived: sum of 4 quarters · filed 2024-05-13
2022-12-31-$137.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12
-$254.00K
derived: sum of 2 quarters · filed 2024-03-12
-$380.00K
derived: sum of 3 quarters · filed 2024-03-12
-$392.00K
10-K · filed 2024-03-12
2022-09-30-$117.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14
-$243.00K
derived: sum of 2 quarters · filed 2023-11-14
-$255.00K
10-Q · filed 2023-11-14
2022-06-30-$126.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11
-$138.00K
10-Q · filed 2023-08-11
2022-03-31-$12.00K
10-Q · filed 2023-05-12
2021-12-31-$80.00K
10-K · filed 2024-03-12
2020-12-31-$604.00K
10-K · filed 2023-03-07

Similar stocks

Stock NameCountryMarket CapPE Ratio
Metagenomi Therapeutics, Inc. (MGX)United States$0.044B-0.48
LeonaBio, Inc. (LONA)United States$0.047B-0.61
Instil Bio, Inc. (TIL)United States$0.048B-1.73
Tevogen Inc. (TVGN)United States$0.049B
aTYR PHARMA INC (ATYR)United States$0.033B-0.98
Quince Therapeutics, Inc. (QNCX)United States$0.031B
CEL SCI CORP (CVM)United States$0.030B-0.81
Inmune Bio, Inc. (INMB)United States$0.056B-2.48
ImageneBio, Inc. (IMA)United States$0.056B-1.31
BioAtla, Inc. (BCAB)United States$0.058B-0.21